🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

The Effect of 0.1% Topical Ciclosporin A for 12-weeks on the Eye Surface Immune Cells in Dry Eyes

RecruitingNAAges 18 Years - anyAllThe University of New South Wales
NCT06898853 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Dry eye disease (DED) is a common, long-lasting condition that affects the surface of the eye. It happens when there's a problem with tear production or quality, which can lead to inflammation and discomfort. The immune system plays a big role in how DED develops and continues. Researchers have found that in people with DED, there are more immune cells and inflammatory substances in the tears and on the eye's surface. This includes various types of immune cells, like T cells and dendritic cells, which are part of the body's defense system. The first treatment for DED is usually artificial tears, but because the condition is chronic and can flare up, clinicians often use anti-inflammatory treatments too. One such treatment is cyclosporine A (CsA), which comes as eye drops. CsA works by reducing inflammation and affects how immune cells behave. Researchers can study the immune cells on

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. 18 years of age and above 2. Participants should meet any two of the following DED diagnostic criteria: i) ocular surface disease index score of ≥23 and ii) Oxford staining score of ≥1 iii) Tear meniscus height \< 0.2 mm. Exclusion Criteria: 1. Participants currently using or with previous use of steroids, ciclosporin, lifitegrast or any anti-inflammatory eye drops in the last 6 months. 2. Participants with systemic CsA or tacrolimus 3. Known hypersensitivity or contraindication to the study medication or any of its ingredients. 4. Active intraocular inflammation. 5. Contact lens wear or the use of contact lenses in the last 4 weeks. 6. Active eye infections or history of critical illness. 7. DED secondary to Steven-Johnson syndrome and cicatricial conjunctival disease. 8. Participants with other ocular co-morbidities and medications for glaucoma. 9. Participants with previous history of ocular surgery in the past 6 months. 10. Any other active or inactive systemic condition, structural abnormality such as eyelid malposition's that in the judgment of the investigator could confound study assessments or limit compliance. 11. Pregnant/breastfeeding women
💊

What it tests

  • 0.1% Ciclosporin A eye drops
  • Mineral oils eye drops
📍

Where

1 site
School of Optometry and Vision Science
Sydney, Australia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy